What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer?
Aron Goldhirsch*, Richard D Gelber and Alan S Coates
Correspondence *Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
Email aron.goldhirsch@ibcsg.org
This article has no abstract so we have provided the first paragraph of the full text.
Improved survival due to adjuvant systemic therapies for women with early breast cancer is among the most important achievements of medical oncology. Adjuvant therapies are prescribed based on information from randomized trials, though it is impossible at the time of treatment to be sure of their efficacy for the individual patient. The 2000 EBCTCG Breast Cancer Overview includes a valuable long-term follow-up of all available results from 194 randomized trials that commenced before 1995 examining adjuvant polychemotherapy, tamoxifen, and ovarian-function suppression. The results clearly show a substantial 15-year survival benefit, extending conclusions serially reported since 1984–1985 and justifying the maintenance of this unique data collection.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.